Roche

News

Roche sticks with molecular glue, partnering Monte Rosa

Roche seems determined to develop a commanding position in the emerging molecular glue category, signing up to a $2 billion partnership with Monte Rosa Therapeutics that i

News

Roche builds gene therapy portfolio with SpliceBio deal

Roche’s gene therapy unit Spark has added to its pipeline in inherited retinal diseases (IRDs) with a $216 million alliance with Spanish biotech SpliceBio.

News

Roche app relieves diabetes distress in clinical trial

A digital health application (DiGA) has been shown to relieve the distress that patients can experience when managing diabetes, which can compromise their care, in a rando

News

Biogen claims first with FDA nod for biosimilar Actemra

Biogen says it is the first drugmaker in the US to get FDA approval for a biosimilar of Roche’s $3 billion blockbuster product Actemra.

News

FDA starts swift review of Regeneron’s CD20 bispecific

The FDA has started a priority review of Regeneron’s CD20xCD3 bispecific antibody odronextamab, seeking a broader label than other drugs in the class.

News

Roche inks pipeline deals with Orionis, PeptiDream

Roche has bolstered its R&D pipeline in oncology and neuroscience with a pair of partnerships with Orionis Biosciences and PeptiDream, parting with upfront cash of $87

Roche sticks with molecular glue, partnering Monte Rosa

Roche builds gene therapy portfolio with SpliceBio deal

Roche app relieves diabetes distress in clinical trial

Biogen claims first with FDA nod for biosimilar Actemra

FDA starts swift review of Regeneron’s CD20 bispecific

Roche inks pipeline deals with Orionis, PeptiDream

AZ's gMG drug Klygefa nears EU approval

Discover a new era of healthcare panel engagement: Grounded ...

Roche

Editor's Picks